Search Results - "Cross, P. C."

Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking by Dawoud, Ahmed A. Z., Tapper, William J., Cross, Nicholas C. P.

“…We sought to determine the significance of myeloid clonal hematopoiesis (CH) in the UK Biobank cohort ( n  = 502,524, median age = 58 years). Utilizing SNP…”
Get full text

Experimental evidence for the co-evolution of hominin tool-making teaching and language by Morgan, T. J. H., Uomini, N. T., Rendell, L. E., Chouinard-Thuly, L., Street, S. E., Lewis, H. M., Cross, C. P., Evans, C., Kearney, R., de la Torre, I., Whiten, A., Laland, K. N.

“…Hominin reliance on Oldowan stone tools—which appear from 2.5 mya and are believed to have been socially transmitted—has been hypothesized to have led to the…”
Get full text

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders by Cross, Nicholas C P, Ernst, Thomas, Chase, Andrew J, Score, Joannah, Hidalgo-Curtis, Claire E, Bryant, Catherine, Jones, Amy V, Waghorn, Katherine, Zoi, Katerina, Ross, Fiona M, Reiter, Andreas, Hochhaus, Andreas, Drexler, Hans G, Duncombe, Andrew, Cervantes, Francisco, Oscier, David, Boultwood, Jacqueline, Grand, Francis H

“…Abnormalities of chromosome 7q are common in myeloid malignancies, but no specific target genes have yet been identified. Here, we describe the finding of…”
Get full text

HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions by Bruford, Elspeth A., Antonescu, Cristina R., Carroll, Andrew J., Chinnaiyan, Arul, Cree, Ian A., Cross, Nicholas C. P., Dalgleish, Raymond, Gale, Robert Peter, Harrison, Christine J., Hastings, Rosalind J., Huret, Jean-Loup, Johansson, Bertil, Le Beau, Michelle, Mecucci, Cristina, Mertens, Fredrik, Verhaak, Roel, Mitelman, Felix

“…Gene fusions have been discussed in the scientific literature since they were first detected in cancer cells in the early 1980s. There is currently no…”
Get full text

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients by Guglielmelli, P, Lasho, T L, Rotunno, G, Score, J, Mannarelli, C, Pancrazzi, A, Biamonte, F, Pardanani, A, Zoi, K, Reiter, A, Duncombe, A, Fanelli, T, Pietra, D, Rumi, E, Finke, C, Gangat, N, Ketterling, R P, Knudson, R A, Hanson, C A, Bosi, A, Pereira, A, Manfredini, R, Cervantes, F, Barosi, G, Cazzola, M, Cross, N C P, Vannucchi, A M, Tefferi, A

“…We recently defined a high-molecular risk category (HMR) in primary myelofibrosis (PMF), based on the presence of at least one of the five ‘prognostically…”
Get full text

EZH2 mutational status predicts poor survival in myelofibrosis by Guglielmelli, Paola, Biamonte, Flavia, Score, Joannah, Hidalgo-Curtis, Claire, Cervantes, Francisco, Maffioli, Margherita, Fanelli, Tiziana, Ernst, Thomas, Winkelman, Nils, Jones, Amy V., Zoi, Katerina, Reiter, Andreas, Duncombe, Andrew, Villani, Laura, Bosi, Alberto, Barosi, Giovanni, Cross, Nicholas C.P., Vannucchi, Alessandro M.

“…We genotyped 370 subjects with primary myelofibrosis (PMF) and 148 with postpolycythemia vera/postessential thrombocythemia (PPV/PET) MF for mutations of EZH2…”
Get full text

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia by ITZYKSON, Raphaël, KOSMIDER, Olivier, VEY, Norbert, BRAUN, Thorsten, HAFERLACH, Torsten, DREYFUS, François, CROSS, Nicholas C. P, PREUDHOMME, Claude, BERNARD, Olivier A, FONTENAY, Michaela, VAINCHENKER, William, SCHNITTGER, Susanne, RENNEVILLE, Aline, BIRNBAUM, Daniel, DROIN, Nathalie, SOLARY, Eric, GELSI-BOYER, Véronique, MEGGENDORFER, Manja, MORABITO, Margot, BERTHON, Céline, ADES, Lionel, FENAUX, Pierre, BEYNE-RAUZY, Odile

“…Several prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutations-including ASXL1-have…”
Get full text

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms by Score, Joannah, Hidalgo-Curtis, Claire, Jones, Amy V., Winkelmann, Nils, Skinner, Alison, Ward, Daniel, Zoi, Katerina, Ernst, Thomas, Stegelmann, Frank, Döhner, Konstanze, Chase, Andrew, Cross, Nicholas C.P.

“…The polycomb repressive complex 2 (PRC2) is a highly conserved histone H3 lysine 27 methyltransferase that regulates the expression of developmental genes…”
Get full text

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms by Wang, Y Lynn, Zoi, Katerina, Pahl, Heike L, Cario, Holger, Reiter, Andreas, Jones, Amy V, Collins, Andrew, Grand, Francis, Silver, Richard T, Chase, Andrew, Cross, Nicholas C P, Oscier, David

“…Chronic myeloproliferative neoplasms (MPNs) are a group of related conditions characterized by the overproduction of cells from one or more myeloid lineages…”
Get full text

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials by Branford, Susan, Fletcher, Linda, Cross, Nicholas C.P., Müller, Martin C., Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald P., Saglio, Giuseppe, Pane, Fabrizio, Kamel-Reid, Suzanne, Wang, Y. Lynn, Press, Richard D., Lynch, Kevin, Rudzki, Zbigniew, Goldman, John M., Hughes, Timothy

“…An international basis for comparison of BCR-ABL mRNA levels is required for the common interpretation of data derived from individual laboratories. This will…”
Get full text

Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable by Zoi, Katerina, Cross, Nicholas C. P.

“…According to the 2008 WHO classification, the category of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) includes atypical chronic myeloid leukaemia…”
Get full text

KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis by Arock, M, Sotlar, K, Akin, C, Broesby-Olsen, S, Hoermann, G, Escribano, L, Kristensen, T K, Kluin-Nelemans, H C, Hermine, O, Dubreuil, P, Sperr, W R, Hartmann, K, Gotlib, J, Cross, N C P, Haferlach, T, Garcia-Montero, A, Orfao, A, Schwaab, J, Triggiani, M, Horny, H-P, Metcalfe, D D, Reiter, A, Valent, P

“…Although acquired mutations in KIT are commonly detected in various categories of mastocytosis, the methodologies applied to detect and quantify the mutant…”
Get full text

Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia by Abecasis, Manuel, Cross, Nicholas C. P., Brito, Manuel, Ferreira, Isabelina, Sakamoto, Kathleen M., Hijiya, Nobuko, Score, Joannah, Gale, Robert Peter

“…Our concept of cancer latency, the interval from when a cancer starts until it is diagnosed, has changed dramatically. A prior widely-used definition was the…”
Get full text

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission by Machova Polakova, Katerina, Zizkova, Hana, Zuna, Jan, Motlova, Eliska, Hovorkova, Lenka, Gottschalk, Andrea, Glauche, Ingmar, Koblihova, Jitka, Pecherkova, Pavla, Klamova, Hana, Stastna Markova, Marketa, Srbova, Dana, Benesova, Adela, Polivkova, Vaclava, Jurcek, Tomas, Zackova, Daniela, Mayer, Jiri, Ernst, Thomas, Mahon, Francois X., Saussele, Susanne, Roeder, Ingo, Cross, Nicholas C. P., Hochhaus, Andreas

“…This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on…”
Get full text

Social living mitigates the costs of a chronic illness in a cooperative carnivore by Almberg, E. S, Cross, P. C, Dobson, A. P, Smith, D. W, Metz, M. C, Stahler, D. R, Hudson, P. J, Festa‐Bianchet, Marco

“…Infection risk is assumed to increase with social group size, and thus be a cost of group living. We assess infection risk and costs with respect to group size…”
Get full text

Harmonization of molecular monitoring of CML therapy in Europe by Müller, M C, Cross, N C P, Erben, P, Schenk, T, Hanfstein, B, Ernst, T, Hehlmann, R, Branford, S, Saglio, G, Hochhaus, A

“…The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at…”
Get full text

Agent-based models of the cultural evolution of occupational gender roles by Cross, C P, Boothroyd, L G, Jefferson, C A

“…The causes of sex differences in human behaviour are contested, with 'evolutionary' and 'social' explanations often being pitted against each other in the…”
Get full text

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations by Bench, Anthony J., White, Helen E., Foroni, Letizia, Godfrey, Anna L., Gerrard, Gareth, Akiki, Susanna, Awan, Abida, Carter, Ian, Goday‐Fernandez, Andrea, Langabeer, Stephen E., Clench, Tim, Clark, Jordan, Evans, Paul A., Grimwade, David, Schuh, Anna, McMullin, Mary F., Green, Anthony R., Harrison, Claire N., Cross, Nicholas C. P.

“…Summary Molecular genetic assays for the detection of the JAK2 V617F (c.1849G>T) and other pathogenetic mutations within JAK2 exon 12 and MPL exon 10 are part…”
Get full text

The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes by Moyo, Tamara K, Mendler, Jason H, Itzykson, Raphael, Kishtagari, Ashwin, Solary, Eric, Seegmiller, Adam C, Gerds, Aaron T, Ayers, Gregory D, Dezern, Amy E, Nazha, Aziz, Valent, Peter, van de Loosdrecht, Arjan A, Onida, Francesco, Pleyer, Lisa, Cirici, Blanca Xicoy, Tibes, Raoul, Geissler, Klaus, Komrokji, Rami S, Zhang, Jing, Germing, Ulrich, Steensma, David P, Wiseman, Daniel H, Pfeilstöecker, Michael, Elena, Chiara, Cross, Nicholas C P, Kiladjian, Jean-Jacques, Luebbert, Michael, Mesa, Ruben A, Montalban-Bravo, Guillermo, Sanz, Guillermo F, Platzbecker, Uwe, Patnaik, Mrinal M, Padron, Eric, Santini, Valeria, Fenaux, Pierre, Savona, Michael R

“…Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) comprise several rare hematologic malignancies with shared concomitant dysplastic and proliferative…”
Get full text

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA by White, Helen E., Matejtschuk, Paul, Rigsby, Peter, Gabert, Jean, Lin, Feng, Lynn Wang, Y., Branford, Susan, Müller, Martin C., Beaufils, Nathalie, Beillard, Emmanuel, Colomer, Dolors, Dvorakova, Dana, Ehrencrona, Hans, Goh, Hyun-Gyung, El Housni, Hakim, Jones, Dan, Kairisto, Veli, Kamel-Reid, Suzanne, Kim, Dong-Wook, Langabeer, Stephen, Ma, Edmond S.K., Press, Richard D., Romeo, Giuliana, Wang, Lihui, Zoi, Katerina, Hughes, Timothy, Saglio, Giuseppe, Hochhaus, Andreas, Goldman, John M., Metcalfe, Paul, Cross, Nicholas C.P.

“…Serial quantitation of BCR-ABL mRNA levels is an important indicator of therapeutic response for patients with chronic myelogenous leukemia and Philadelphia…”
Get full text